ORKA vs. TARS, BEAM, CNTA, ARQT, ADPT, IMCR, SPRY, EWTX, SDGR, and BHVN
Should you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Schrodinger (SDGR), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.
Oruka Therapeutics vs. Its Competitors
Tarsus Pharmaceuticals (NASDAQ:TARS) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.
90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Tarsus Pharmaceuticals presently has a consensus target price of $66.67, suggesting a potential upside of 64.55%. Oruka Therapeutics has a consensus target price of $40.38, suggesting a potential upside of 225.21%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Tarsus Pharmaceuticals.
Oruka Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Oruka Therapeutics' return on equity of -25.66% beat Tarsus Pharmaceuticals' return on equity.
In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 2 articles in the media. Oruka Therapeutics' average media sentiment score of 1.89 beat Tarsus Pharmaceuticals' score of 1.88 indicating that Oruka Therapeutics is being referred to more favorably in the news media.
Tarsus Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the S&P 500.
Oruka Therapeutics has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Oruka Therapeutics beats Tarsus Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get Oruka Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oruka Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ORKA) was last updated on 7/2/2025 by MarketBeat.com Staff
Free ORKA Stock Alerts